TARPEYO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8491932 | CALLIDITAS | Compositions for the oral delivery of corticosteroids |
May, 2029
(5 years from now) | |
Tarpeyo is owned by Calliditas.
Tarpeyo contains Budesonide.
Tarpeyo has a total of 1 drug patent out of which 0 drug patents have expired.
Tarpeyo was authorised for market use on 15 December, 2021.
Tarpeyo is available in capsule, delayed release;oral dosage forms.
Tarpeyo can be used as treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression.
The generics of Tarpeyo are possible to be released after 20 December, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-389) | Dec 15, 2028 |
| Orphan Drug Exclusivity(ODE-464) | Dec 20, 2030 |
| New Product(NP) | Dec 15, 2024 |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 15 December, 2021
Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression
Dosage: CAPSULE, DELAYED RELEASE;ORAL
More Information on Dosage
TARPEYO family patents
